Sugi Predict

Sugi Predict / Compounds / Ciprostene

Ciprostene

Ciprostene

SCHEMBL34269

CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@]2(C)C/C(=C\CCCC(=O)O)C[C@H]12

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ PPARG P37231 1/20 0.61
▸ PPARD Q03181 1/20 0.61
▸ PPARA Q07869 1/20 0.61
▸ ALDH1A1 P00352 6/20 0.60
▸ PTGIR P43119 6/20 0.52
▸ PTGER4 P35408 5/20 0.52
▸ PTGER2 P43116 4/20 0.52
▸ TSHR P16473 3/20 0.52
▸ PTGER1 P34995 3/20 0.52
▸ PTGER3 P43115 3/20 0.52
▸ HPGD P15428 2/20 0.52
▸ TBXA2R P21731 2/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ PTGFR P43088 2/20 0.52
▸ NR1I2 O75469 1/20 0.52
▸ ESR1 P03372 1/20 0.52
▸ PGR P06401 1/20 0.52
▸ OPRK1 P41145 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ciprostene SCHEMBL361116 0.99 MEN1 (0.60) MEN1KMT2APPARGPPARDPPARA
Ciprostene SCHEMBL4428358 0.91 MEN1 (0.50) MEN1KMT2APPARGPPARDPPARA
Ciprostene SCHEMBL667640 0.91 MEN1 (0.50) MEN1KMT2APPARGPPARDPPARA
SCHEMBL11891875 0.90 MEN1 (0.47) MEN1KMT2APPARGPPARDPPARA
Carbacyclin SCHEMBL24340889 0.76 PPARD (1.00) MEN1KMT2APPARGPPARDPPARA
Carbacyclin SCHEMBL6082848 0.76 PPARD (1.00) MEN1KMT2APPARGPPARDPPARA
Carbacyclin SCHEMBL13539945 0.76 PPARD (1.00) MEN1KMT2APPARGPPARDPPARA
Carbacyclin SCHEMBL10439712 0.76 PPARD (1.00) MEN1KMT2APPARGPPARDPPARA
Carbacyclin SCHEMBL6172952 0.76 PPARD (1.00) MEN1KMT2APPARGPPARDPPARA
Carbacyclin SCHEMBL10732794 0.76 PPARD (1.00) MEN1KMT2APPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111658628-B Application of GLI2 inhibitor and screening method of compound inhibiting GLI2 中国科学院动物研究所 2022-03-01 — — CN claimed
EP-3661602-B1 PHOSPHOLIPID ANALOGUES KARL FRANZENS UNIV GRAZ (AT) 2021-05-26 — — EP claimed
US-10954255-B2 Phospholipid analogues KARL-FRANZENS-UNIVERSITAET GRAZ (AT) 2021-03-23 — — US claimed
EP-3661602-A1 PHOSPHOLIPID ANALOGUES Karl-Franzens-Universität Graz (AT) 2020-06-10 — — EP claimed
US-20200157127-A1 Phospholipid Analogues KARL-FRANZENS-UNIVERSITAET GRAZ (AT) 2020-05-21 — — US claimed
WO-2019025324-A1 PHOSPHOLIPID ANALOGUES Karl-Franzens-Universität Graz (AT) 2019-02-07 — — WO claimed
US-20160368895-A1 PULMONARY HYPERTENSION TREATING AGENT THE UNIVERSITY OF TOKYO (JP) 2016-12-22 — — US claimed
CN-104244902-A Sample collection devices with blood stabilizing agents BECTON DICKINSON CO 2014-12-24 — — CN claimed
EP-2809289-A1 SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS Becton, Dickinson and Company (US) 2014-12-10 — — EP claimed
US-20130209985-A1 SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS BECTON, DICKINSON AND COMPANY 2013-08-15 — — US claimed
US-5654339-A ANTIARTHRITIC AGENT SCHERING AKTIENGESELLSCHAFT (DE) 1997-08-05 — — US claimed
EP-0686036-B1 USE OF PROSTANE DERIVATIVES OF FORMULAE I AND II FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC POLYARTHRITIS SCHERING AG (DE) 1997-03-12 — — EP claimed
EP-0510080-A4 PRODRUG ANHYDRIDES OF ASPRIN, INDOMETHACIN AND IBUPROFEN, THEIR PREPARATION, COMPOSITIONS, AND ANTI-INFLAMMATORY METHOD OF USE — 1992-12-02 — — EP claimed
EP-0510080-A1 PRODRUG ANHYDRIDES OF ASPRIN, INDOMETHACIN AND IBUPROFEN, THEIR PREPARATION, COMPOSITIONS, AND ANTI-INFLAMMATORY METHOD OF USE NOVA PHARMACEUTICAL CORPORATION (US) 1992-10-28 — — EP claimed
WO-1991009831-A1 PRODRUG ANHYDRIDES OF ASPRIN, INDOMETHACIN AND IBUPROFEN, THEIR PREPARATION, COMPOSITIONS, AND ANTI-INFLAMMATORY METHOD OF USE NOVA PHARMACEUTICAL CORPORATION (US) 1991-07-11 — — WO claimed
EP-0217419-B1 REDUCTION OF DYSFUNCTION IN ANGIOPLASTY PROCEDURES SEE/SHELL BIOTECHNOLOGY, INC. (US) 1991-04-10 — — EP claimed
US-4820732-A INJECTING PROSTAGLANDINS BEFORE, DURING, AND AFTER SURGERY THE UPJOHN COMPANY (US) 1989-04-11 — — US claimed
EP-0278977-A1 PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS. BUNDGAARD HANS (DK) 1988-08-24 — — EP claimed
WO-1988001615-A1 PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS BUNDGAARD HANS (DK) 1988-03-10 — — WO claimed
EP-0217419-A2 Reduction of dysfunction in angioplasty procedures SEE/SHELL BIOTECHNOLOGY, INC. (US) 1987-04-08 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954255-B2 Phospholipid analogues ELOVL3, SGMS1, FFAR3 MEN1 4364/4885KMT2A 1061/4885PPARG 248/4885
US-20200157127-A1 Phospholipid Analogues ELOVL3, SGMS1, FFAR3 MEN1 4364/4885KMT2A 1061/4885PPARG 248/4885
US-20160368895-A1 PULMONARY HYPERTENSION TREATING AGENT PTGIR, AGTR1, PTGER1 MEN1 3683/4885KMT2A 3077/4885PPARG 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.